BMS-538203

CAS No. 543730-41-2

BMS-538203( BMS538203 | BMS 538203 )

Catalog No. M14950 CAS No. 543730-41-2

A chemical intermidate of BMS-626529, a HIV-1 attachment inhibitor that targets gp120,

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1053 Get Quote
50MG 2142 Get Quote
100MG 2790 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BMS-538203
  • Note
    Research use only, not for human use.
  • Brief Description
    A chemical intermidate of BMS-626529, a HIV-1 attachment inhibitor that targets gp120,
  • Description
    A chemical intermidate of BMS-626529, a HIV-1 attachment inhibitor that targets gp120.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BMS538203 | BMS 538203
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    543730-41-2
  • Formula Weight
    269.2258
  • Molecular Formula
    C12H12FNO5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 54 mg/mL
  • SMILES
    O=C(O)/C(O)=C/C(N(CC1=CC=C(F)C=C1)OC)=O
  • Chemical Name
    2-Butenoic acid, 4-[[(4-fluorophenyl)methyl]methoxyamino]-2-hydroxy-4-oxo-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Nowicka-Sans B, et al. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507.
molnova catalog
related products
  • Des(benzylpyridyl) A...

    Atazanavir is an highly potent HIV-1 protease inhibitor.

  • Fostemsavir Tris

    Fostemsavir Tris is the prodrug of BMS-626529,is a oral, safe and effective?inhibitor of HIV-1 attachment.?It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells.

  • GS-6207

    GS-6207 (GS6207, GS-CA1) is a potent, selective inhibitor of HIV-1 capsid function with potency and potential to be clinically effective against a broad range of HIV-1 strains.